CM-101 is under clinical development by Chemomab Therapeutics and currently in Phase II for Systemic Sclerosis (Scleroderma). According to GlobalData, Phase II drugs for Systemic Sclerosis (Scleroderma) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CM-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CM-101 is under development for the treatment of systemic sclerosis, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, idiopathic pulmonary fibrosis, primary sclerosing cholangitis COVID-19 pneumonia, and severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). The drug candidate is a humanized monoclonal antibody devoid of T cell epitopes. It is developed based on composite human antibody technology. The drug candidate targets CCL24. It is administered through intravenous and subcutaneous route.
Chemomab Therapeutics overview
Chemomab Therapeutics (Chemomab), formerly Anchiano Therapeutics Ltd, is a preclinical stage biopharmaceutical company that focuses on the discovery, development, and commercialization of therapies for the unmet needs of fibrotic and inflammatory diseases. Its pipeline drug candidate is CM-101 focused on CCL24 that is advanced in PSC and SSc orphan indications. The company operates subsidiaries in Israel and Delaware. Chemomab is headquartered in Tel Aviv-Yafo, Tel Aviv, Israel.
For a complete picture of CM-101’s drug-specific PTSR and LoA scores, buy the report here.